


The severe asthma pathway for NHS Highland*


Primary care management



Secondary care management vetting



Secondary care clinic assessment^{2,3†}



Governance and data collection

Collect a comprehensive dataset for all patients discussed at severe asthma MDT, and at review touchpoints. Switch of biologic therapy should be carried out through a comprehensive review by the severe asthma MDT

Biologic assessment tool decisions should be made via severe asthma MDT processes

Refer to SMC recommendations and local formulary guidance



*Tests to be undertaken as per local/regional pathways or pre-clinic screening agreements. If available, does not exclude from onward referral.

†Please refer to relevant SmPC before prescribing.

ABPA, Allergic bronchopulmonary aspergillosis; ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; AQLQ, Asthma Quality of Life Questionnaire; BLF, British Lung Foundation; BMI, body mass index; CRSwNP, Chronic rhinosinusitis with nasal polyps; CV, cardiovascular; ED, emergency department; EGPA, Eosinophilic granulomatosis with polyangiitis; ENT, ear, nose and throat; Eos, eosinophils; FBC, full blood count; FeNO, fractional exhaled nitric oxide; GI, gastrointestinal; GORD, gastro-oesophageal reflux disease; HRCT, high-resolution computed tomography; ICS, inhaled corticosteroid(s); Ig, immunoglobulin; IL, interleukin; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LFT, liver function test; mOCS, maintenance oral corticosteroids; MDT, multidisciplinary team; OCS, oral corticosteroid(s); OOH, out of hours; PEFR, peak expiratory flow rate; PFT, pulmonary function test; ppb, parts per billion; QoL, Quality of Life; R, receptor; SABA, short-acting β2-agonist; SLT, speech and language therapy; SMC, Scottish medicines consortium; TH2, type 2 helper; U&E, urea and electrolytes 1